Advocate Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.24M Sell
160,303
-6,653
-4% -$382K 1.39% 29
2026
Q1
$10.1M Buy
166,956
+1,286
+0.8% +$75K 1.58% 17
2025
Q4
$8.94M Buy
165,670
+9,076
+6% +$437K 1.45% 25
2025
Q3
$7.06M Buy
156,594
+2,355
+2% +$110K 1.16% 37
2025
Q2
$7.14M Buy
154,239
+7,088
+5% +$348K 1.28% 35
2025
Q1
$8.97M Buy
147,151
+1,974
+1% +$115K 1.64% 18
2024
Q4
$8.21M Buy
145,177
+7,936
+6% +$443K 1.55% 23
2024
Q3
$7.1M Buy
137,241
+2,873
+2% +$135K 1.29% 34
2024
Q2
$5.58M Buy
134,368
+7,644
+6% +$342K 1.12% 39
2024
Q1
$6.87M Buy
126,724
+16,497
+15% +$840K 1.37% 30
2023
Q4
$5.66M Buy
110,227
+5,664
+5% +$297K 1.21% 33
2023
Q3
$6.07M Sell
104,563
-2,643
-2% -$162K 1.41% 27
2023
Q2
$6.86M Buy
107,206
+814
+0.8% +$54.6K 1.51% 21
2023
Q1
$7.37M Buy
106,392
+1,333
+1% +$94K 1.61% 20
2022
Q4
$7.56M Buy
105,059
+7,773
+8% +$586K 1.63% 19
2022
Q3
$6.92M Buy
97,286
+7,998
+9% +$580K 1.71% 19
2022
Q2
$6.88M Buy
+89,288
New +$6.8M 1.6% 20

Other funds holding BMY

Advocate Group's BMY Position: Q2 2026 in Review

Advocate Group reduced its Bristol-Myers Squibb (BMY) stake by 4% in Q2 2026, selling an estimated $382K and leaving 160,303 shares worth $9.24M. The position accounts for 1.39% of the portfolio, ranked #29.

Advocate Group first reported a position in BMY in Q2 2022 and has held it in 17 quarters since. The position peaked at $10.1M in Q1 2026. 800 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Advocate Group held 160,303 shares of Bristol-Myers Squibb worth $9.24M as of Q2 2026.
  • Advocate Group sold 6,653 Bristol-Myers Squibb shares in Q2 2026, an estimated $382K.
  • Bristol-Myers Squibb made up 1.39% of Advocate Group's portfolio in Q2 2026, its #29 holding.
  • Advocate Group first reported a position in Bristol-Myers Squibb in Q2 2022 and has held it in 17 quarters since.
  • Advocate Group's Bristol-Myers Squibb position peaked at $10.1M in Q1 2026.
  • 800 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Advocate Group's 13F filing for Q2 2026, filed 17 Jul 2026.